Eli Lilly's animal health division Elanco recently filed for a US offering that should come in the fall, raising as much as $3 billion in what may be the year's biggest IPO.
Elanco mainly competes with three other giant global animal health companies. Zoetis is the #1 player with a roughly 15% global market share, followed by Boehringer Ingelheim (14%), Merck (11%) and Elanco (8%). Spun out of Pfizer in 2013, Zoetis is the only publicly-traded peer. It trades 249% above its offer price; including dividends, Zoetis has returned over 26% annually.
To read the entire article, sign up for a free 7-day trial of IPO Pro, the single, most effective IPO data platform you'll ever need.
When to expect the Elanco IPO
Because it did not submit a confidential filing, we expect Elanco to wait until at least October to go public. In addition, Elanco will have to find a CFO; its previous CFO went on medical leave days before the IPO filing.
Fall IPO Preview
Elanco is just one IPO we are highlighting in our upcoming Fall 2018 IPO Preview. Look for the special report in early September, available only for IPO Pro subscribers.
